Allarity Therapeutics, Inc.
ALLRNASDAQHealthcare● Active
$1.58
$-0.03(-1.86%)
Market Cap$25138944
P/E Ratio—
52W High$2.35
52W Low$0.769
Allarity Therapeutics, Inc. (ALLR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ALLR · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.17
Est. -$0.22 · +22.7%
Revenue
$0.00B
Est. $0.00B · +0.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS🔥 6-Quarter EPS Beat Streak
ALLR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 21, 2026 | -$0.25 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.22 | -$0.17 | +22.7% | $0.00B | $0.00B | +0.0% |
| ▲ Q1 FY2026 | Mar 31, 2026 | -$0.22 | -$0.19 | +13.6% | $0.00B | $0.00B | +0.0% |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$0.23 | -$0.19 | +17.4% | — | — | — |
| ▲ Q3 FY2025 | Aug 15, 2025 | -$0.21 | -$0.15 | +28.6% | — | — | — |
| — Q2 FY2025 | May 9, 2025 | — | -$0.25 | — | — | — | — |
| ▲ Q2 FY2025 | Apr 4, 2025 | -$8.10 | -$4.73 | +41.6% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$8.52 | -$7.71 | +9.5% | — | — | — |
Q3 FY2026
Aug 21, 2026
EPS Actual
—
EPS Est.
-$0.25
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.17
EPS Est.
-$0.22
EPS Surpr.
+22.7%
Revenue
$0.00B
Q1 FY2026
Mar 31, 2026Beat
EPS Actual
-$0.19
EPS Est.
-$0.22
EPS Surpr.
+13.6%
Revenue
$0.00B
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$0.19
EPS Est.
-$0.23
EPS Surpr.
+17.4%
Revenue
—
Q3 FY2025
Aug 15, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$0.21
EPS Surpr.
+28.6%
Revenue
—
Q2 FY2025
May 9, 2025
EPS Actual
-$0.25
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
Apr 4, 2025Beat
EPS Actual
-$4.73
EPS Est.
-$8.10
EPS Surpr.
+41.6%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$7.71
EPS Est.
-$8.52
EPS Surpr.
+9.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q3 FY2027 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q2 FY2027 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q1 FY2027 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q4 FY2026 | $-0.25 | $-0.25 | $-0.25 | 1 |
| Q3 FY2026 | $-0.25 | $-0.25 | $-0.25 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +22.7% | $1.51 | $1.35 | -10.60% |
| ▲ Q1 FY2026 | Mar 31, 2026 | +13.6% | $1.04 | $1.09 | +4.81% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +17.4% | $1.19 | $1.18 | -0.84% |
| ▲ Q3 FY2025 | Aug 15, 2025 | +28.6% | $0.98 | $0.96 | -2.22% |
| — Q2 FY2025 | May 9, 2025 | — | $1.07 | $1.05 | -1.87% |
| ▲ Q2 FY2025 | Apr 4, 2025 | +41.6% | $0.82 | $0.79 | -3.70% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +9.5% | $1.45 | $1.41 | -2.76% |
| ▼ Q3 FY2024 | Aug 5, 2024 | -1037.9% | $4.84 | $4.64 | -4.13% |
Q2 FY2026-10.60%
Report Date
May 15, 2026
EPS Beat/Miss
+22.7%
Price Before
$1.51
Price After
$1.35
Q1 FY2026+4.81%
Report Date
Mar 31, 2026
EPS Beat/Miss
+13.6%
Price Before
$1.04
Price After
$1.09
Q4 FY2025-0.84%
Report Date
Nov 14, 2025
EPS Beat/Miss
+17.4%
Price Before
$1.19
Price After
$1.18
Q3 FY2025-2.22%
Report Date
Aug 15, 2025
EPS Beat/Miss
+28.6%
Price Before
$0.98
Price After
$0.96
Q2 FY2025-1.87%
Report Date
May 9, 2025
EPS Beat/Miss
—
Price Before
$1.07
Price After
$1.05
Q2 FY2025-3.70%
Report Date
Apr 4, 2025
EPS Beat/Miss
+41.6%
Price Before
$0.82
Price After
$0.79
Q4 FY2024-2.76%
Report Date
Nov 14, 2024
EPS Beat/Miss
+9.5%
Price Before
$1.45
Price After
$1.41
Q3 FY2024-4.13%
Report Date
Aug 5, 2024
EPS Beat/Miss
-1037.9%
Price Before
$4.84
Price After
$4.64
Avg Beat Reaction-2.55%
Avg Miss Reaction-4.13%
Beat Rate6 / 8 quarters
Largest Move-10.60% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ALLR ends December
Allarity Therapeutics, Inc. (ALLR) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.17 — beating the analyst consensus of $-0.22 by +22.7%. ALLR has beaten EPS estimates for 6 consecutive quarters. The next ALLR earnings date is expected around September 1, 2026.
Each quarter, investors track ALLR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ALLR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ALLR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ALLR earnings · 5 questionsAllarity Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. ALLR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ALLR historically reports after market close (AMC).
ALLR earnings datewhen is ALLR earningsALLR next earnings datewhen does ALLR report earningsALLR earnings calendar
▸ Source: FMP · Allarity Therapeutics, Inc. SEC filings · US GAAP · Allarity Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026